The Ministry of Food and Drug Safety imposed manufacturing suspensions beginning July 21 on Samchundang Pharm’s nasal-spray dosage form and Lefurozine Syrup for manufacturing-control and recall-procedure failures.
Korean translation
식품의약품안전처가 제조관리 및 회수절차 위반을 이유로 7월 21일부터 점비액제와 레푸로진시럽 제조업무정지 처분을 부과함.